Lead sponsor
Mayo Clinic
14 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.
14
Trials led
7
Active
387,085
Total enrollment
2
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
4
Phase 3
2
Phase 4
7
Not applicable
1
Trials by status
By invitation
2
Recruiting
4
Active, not recruiting
1
Completed
6
Withdrawn
1
Trials led
TrialKey I/E criterionPhaseStatusEnrollment
Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk—not applicableCompleted386,301
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection FractionBMI ≥30Ph 2By invitation81
The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes—Ph 2Recruiting60
The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With ObesityBMI ≥30Ph 4Recruiting40
Pilot Study of the Effect of Liraglutide on Weight Loss and Gastric Functions in ObesityHealthy volunteersPh 2Completed40
Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor FunctionsBMI ≥30Ph 4Active, not recruiting30
Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenBMI ≥30Ph 4By invitation30